Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors.
MRI measures should be a primary outcome endpoint in Phase III randomized, controlled trials in multiple sclerosis: Yes.
RORs in Autoimmune Disease.
Features of sleep disturbances in multiple sclerosis patients.
Constraint-Induced Movement Therapy for the Lower Extremities in Multiple Sclerosis: Case Series with 4-Year Follow-up.
Communication between pathogenic T cells and myeloid cells in neuroinflammatory disease.
Perception of affective prosody in patients at an early stage of relapsing-remitting multiple sclerosis.
Discerning primary and secondary factors responsible for clinical fatigue in multisystem diseases.
Understanding Biomarkers of Neurodegeneration: Ultrasensitive detection techniques pave the way for mechanistic understanding.
Regulatory role of vitamin D in T-cell reactivity against myelin peptides in relapsing-remitting multiple sclerosis patients.
Long-term treatment risks in multiple sclerosis: risk knowledge and risk perception in a large cohort of mitoxantrone-treated patients.
PET imaging in multiple sclerosis.
High-mobility group box 1 up-regulates aquaporin 4 expression via microglia-astrocyte interaction.
Risk of fractures in patients with multiple sclerosis: record-linkage study.
Visualizing iron in multiple sclerosis.
Sleep loss as risk factor for neurologic disorders: A review.
Bilateral differences in lower-limb performance in individuals with multiple sclerosis.
Temporal reorganization to overcome monocular demyelination.
Gait and six-minute walk performance in persons with multiple sclerosis.
SIRT1 is decreased during relapses in patients with multiple sclerosis.
Disability and Fatigue Can Be Objectively Measured in Multiple Sclerosis.
Immunoproteasome-selective inhibitors: a promising strategy to treat hematologic malignancies, autoimmune and inflammatory diseases.
Tumefactive demyelinating lesions as a first clinical event: Clinical, imaging, and follow-up observations.
Discovery of A-971432, an Orally Bioavailable Selective Sphingosine-1-Phosphate Receptor 5 (S1P5) Agonists for the Potential Treatment of Neurodegenerative Disorders.
Comparison between the cranial magnetic resonance imaging features of neuromyelitis optica spectrum disorder versus multiple sclerosis in Taiwanese patients.

Pages